HONG KONG, China I June 15, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III ...

INCHEON, South Korea I June 15, 2025 I Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of ...

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease - ...

SHANGHAI, China I June 15, 2025 I Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study ...

BASEL, Switzerland I June 15, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ ...

WILMINGTON, DE, USA I June 15, 2025 I Incyte (Nasdaq:INCY) today announced the first clinical data from two studies evaluating the safety, tolerability and ...

Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or ...

CAMBRIDGE, MA, USA I June 13, 2025 I Regor Therapeutics Group ("Regor"), a global innovator of clinical-stage biotechnology, today announced that it will ...

(NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company’s respiratory syncytial virus (RSV) vaccine, for the prevention of lower ...

Get the latest biopharma news, clinical trial updates, and industry insights at PipelineReview.com. Discover innovative therapies and regulatory news.

Data highlights potential of ZL-1503 as a promising treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases ...

– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma – – In ...